The target INR range for patients on warfarin therapy varies depending on their condition but is typically between 2.0 and 3.0.

Frequency of testing depends on individual patient needs, but initially, it may be done weekly or bi-weekly until stable, then less frequently thereafter.

Yes, the PT / INR Test can help diagnose various clotting disorders, including those related to liver disease or genetic clotting factor deficiencies.

Medications, dietary changes, liver function, and underlying health conditions can all influence PT / INR results.

Yes, the PT / INR Test is a safe and standard diagnostic procedure used worldwide to monitor blood clotting ability and adjust anticoagulant therapy.

A positive result indicates the presence of Dengue virus NS1 antigen, suggesting acute Dengue infection.

No, the Dengue NS1 test specifically detects Dengue virus NS1 antigen and is not useful for diagnosing other viral infections.

No, the Dengue NS1 test does not differentiate between different Dengue virus serotypes. Additional tests may be required for serotype identification.

The Dengue NS1 test can detect infection within the first 1 to 7 days of symptom onset, when NS1 antigen levels are typically high.

Consult a healthcare provider for further evaluation, as additional tests or clinical assessment may be necessary.

Risks include bleeding, infection, and changes in nasal sensation. Our experienced team takes measures to minimize these risks and ensure a successful outcome.